Ruslana G. Shumak
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Elective First-Line Use of Dimethyl Fumarate in Psoriasis: Insights from an Italian Cohort.
Journal: Dermatology practical & conceptual
Published: June 25, 2025
Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio Experience.
Journal: Dermatology practical & conceptual
Published: January 14, 2025
Challenging case of tinea corporis and faciei in psoriatic patient treated with bimekizumab: The usefulness of mycological screening before biological therapies.
Journal: Medical mycology case reports
Published: October 11, 2024
Role of Nicotinamide in the Pathogenesis of Actinic Keratosis: Implications for NAD+/SIRT1 Pathway.
Journal: Biomolecules
Published: October 03, 2024
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 22, 2024
Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 11, 2024
Epidemiological and clinical analysis of exposure-related factors in non-melanoma skin cancer: A retrospective cohort study.
Journal: Environmental research
Published: November 26, 2023
From In Silico Simulation between TGF-β Receptors and Quercetin to Clinical Insight of a Medical Device Containing Allium cepa: Its Efficacy and Tolerability on Post-Surgical Scars.
Journal: Life (Basel, Switzerland)
Published: July 06, 2023
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis.
Journal: Journal of clinical medicine
Published: April 21, 2022
Certolizumab pegol in pregnant and breastfeeding psoriatic patients.
Journal: Italian journal of dermatology and venereology
Published: March 11, 2022
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
Journal: Dermatologic therapy
Published: December 27, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026